Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer.
Ernest NadalMartín Oré-ArceJordi RemonReyes Bernabé-CaroMarta Covela-RúaJavier de Castro-CarpeñoBartomeu Massutí-SuredaMónica Guillot-MoralesMargarita MajemInmaculada Maestu-MaiquesIdoia Morilla-RuízRegina GironésPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and prevalence among older people, the older adult population is underrepresented in clinical trials. For LC with Epidermal Growth Factor Receptor (EGFR) mutations, there is no clear association of this mutation with age. Geriatric assessments (GAs) and a multidisciplinary approach are essential for defining the optimal treatment. In this consensus, a group of experts selected from the Oncogeriatrics Section of the Spanish Society of Medical Oncology (Sección de Oncogeriatría de la Sociedad Española de Oncología Médica-SEOM), the Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón-GECP) and the Association for Research on Lung Cancer in Women (Asociación para la Investigación del Cáncer de Pulmón en Mujeres-ICAPEM) evaluate the scientific evidence currently available and propose a series of recommendations to optimize the management of older adult patients with advanced LC with EGFR mutations.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- community dwelling
- clinical trial
- middle aged
- physical activity
- simultaneous determination
- small cell lung cancer
- risk factors
- healthcare
- mass spectrometry
- clinical practice
- palliative care
- liquid chromatography
- polycystic ovary syndrome
- pregnant women
- type diabetes
- solid phase extraction
- room temperature
- pregnancy outcomes
- adipose tissue
- open label
- combination therapy
- childhood cancer
- double blind